Literature DB >> 35737163

Effects of Neonatal Administration of Non-Opiate Analogues of Leu-Enkephalin to Heart Tissue Homeostasis of Prepubertal Albino Rats Exposed to Hypoxia.

E N Sazonova1,2, I A Gusev3, Yu B Malofey3, A V Lanshakova3, S V Vdovenko3.   

Abstract

Hypobaric hypoxia (pO2 65 mm Hg, duration 4 h) induced a significant increase in the number of cardiomyocytes expressing р53, beclin-1, endothelial NO synthase and accumulation and degranulation of mast cells in the epicardium in hearts of prepubertal female rats (age 45-47 days); the number of cardiomyocytes with nucleoli decreased, while the number of single-nucleolar cardiomyocytes increased after this exposure. Five-fold administration of non-opiate analogue of leu-enkephalin (NALE peptide: Phe-D-Ala-Gly-Phe-Leu-Arg; 100 μg/kg) during the neonatal period reduced the severity of the post-hypoxic changes in the heart. Neonatal administration of NALE (100 μg/kg) against the background of NO synthase blockade with L-NAME (50 mg/kg) did not abolish the cardioprotective effects of the peptide. A similar correction of posthypoxic changes in the heart was observed after neonatal administration of original peptide G (Phe-D-Ala-Gly-Phe-Leu-Gly; 100 μg/kg). Thus, NO synthase-NO system and C-terminal amino acid Arg in the molecule of non-opiate analogue of leu-enkephalin are not required for the cardioprotective effects of peptides. Non-opiate leu-enkephalin analogs, peptides NALE and G, can be considered as promising substances for increasing heart resistance to hypoxia during later age periods.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  acute hypoxia; apoptosis; cardiomyocytes; leu-enkephalin analogues; mast cells

Mesh:

Substances:

Year:  2022        PMID: 35737163     DOI: 10.1007/s10517-022-05516-0

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  10 in total

Review 1.  Mitochondrial nitric oxide synthase.

Authors:  Pedram Ghafourifar; Enrique Cadenas
Journal:  Trends Pharmacol Sci       Date:  2005-04       Impact factor: 14.819

2.  Participation of opioid receptors in the cytoprotective effect of chronic normobaric hypoxia.

Authors:  N V Naryzhnaya; I Khaliulin; Y B Lishmanov; M S Suleiman; S Y Tsibulnikov; F Kolar; L N Maslov
Journal:  Physiol Res       Date:  2019-01-10       Impact factor: 1.881

3.  Nucleolar stress is an early response to myocardial damage involving nucleolar proteins nucleostemin and nucleophosmin.

Authors:  Daniele Avitabile; Brandi Bailey; Christopher T Cottage; Balaji Sundararaman; Anya Joyo; Michael McGregor; Natalie Gude; Silvia Truffa; Aryan Zarrabi; Mathias Konstandin; Mohsin Khan; Sadia Mohsin; Mirko Völkers; Haruhiro Toko; Matt Mason; Zhaokang Cheng; Shabana Din; Roberto Alvarez; Kimberlee Fischer; Mark A Sussman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

Review 4.  Targeting cardiac mast cells: pharmacological modulation of the local renin-angiotensin system.

Authors:  Alicia C Reid; Jacqueline A Brazin; Christopher Morrey; Randi B Silver; Roberto Levi
Journal:  Curr Pharm Des       Date:  2011-11       Impact factor: 3.116

5.  Chymase inhibition reduces infarction and matrix metalloproteinase-9 activation and attenuates inflammation and fibrosis after acute myocardial ischemia/reperfusion.

Authors:  Shizu Oyamada; Cesario Bianchi; Shinji Takai; Louis M Chu; Frank W Sellke
Journal:  J Pharmacol Exp Ther       Date:  2011-07-27       Impact factor: 4.030

Review 6.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

7.  Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr192 and compromises its cardioprotective activity.

Authors:  Ilona Kareinen; Marc Baumann; Su Duy Nguyen; Katariina Maaninka; Andrey Anisimov; Minoru Tozuka; Matti Jauhiainen; Miriam Lee-Rueckert; Petri T Kovanen
Journal:  J Lipid Res       Date:  2018-03-26       Impact factor: 5.922

8.  Pretreatment with cilnidipine attenuates hypoxia/reoxygenation injury in HL-1 cardiomyocytes through enhanced NO production and action potential shortening.

Authors:  Hiroyuki Minato; Ichiro Hisatome; Yasutaka Kurata; Tomomi Notsu; Naoe Nakasone; Haruaki Ninomiya; Toshihiro Hamada; Takuya Tomomori; Akihiro Okamura; Junichiro Miake; Motokazu Tsuneto; Yasuaki Shirayoshi; Ryo Endo; Akihiro Otsuki; Futoshi Okada; Yoshimi Inagaki
Journal:  Hypertens Res       Date:  2020-01-15       Impact factor: 3.872

9.  Excessive Hypoxia-Inducible Factor-1α Expression Induces Cardiac Rupture via p53-Dependent Apoptosis After Myocardial Infarction.

Authors:  Masataka Ikeda; Tomomi Ide; Tomonori Tadokoro; Hiroko Deguchi Miyamoto; Soichiro Ikeda; Kosuke Okabe; Akihito Ishikita; Midori Sato; Ko Abe; Shun Furusawa; Kosei Ishimaru; Shouji Matsushima; Hiroyuki Tsutsui
Journal:  J Am Heart Assoc       Date:  2021-09-02       Impact factor: 5.501

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.